A Study of BGM0504 in Participants With Obesity
Recruiting
Phase 2
Interventional Study
Obesity
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 90 (estimated)
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* ● Able and willing to provide a written informed consent.
* Male or female subjects, 18-65 years of age at the time of signing informed consent.
* At screening visit, 35.0 ﹤BMI﹤ 45.0 kg/m2;
* Diet and exercise control for at least 3 months before screening visit, and be…
Contacts